Fingolimod News and Research

RSS

Novel molecular link between vitamin B12 and multiple sclerosis revealed in astrocytes

For decades, scientists have noted an intriguing similarity between a deficiency in vitamin B12 – an essential nutrient that supports healthy development and functioning of the central nervous system (CNS) – and multiple sclerosis (MS), a chronic disease in which the body's immune system attacks the CNS and which can produce neurodegeneration.

11 Dec 2023

Novel and emerging therapies offer new hope for patients with inflammatory bowel disease

Ulcerative colitis (UC) and Crohn's disease (CD) are chronic inflammatory bowel diseases (IBD) that affect the gastrointestinal tract.

7 Nov 2023

Insights into the pathophysiological mechanisms governing neuropsychiatric symptoms of multiple sclerosis

Researchers pursued insights into the pathophysiological mechanisms governing neuropsychiatric symptoms of MS.

21 Jul 2023

Research reveals a more effective treatment for multiple sclerosis patients

Degeneration of myelin, an insulating sheath required for rapid communication between nerve cells, and neuroinflammation are notable hallmarks of Multiple Sclerosis (MS) and related neurodegenerative disorders such as Alzheimer's disease or Huntington's disease that affect roughly 2.8 million people in the world.

21 Apr 2023

What is the potential role of sphingosine kinase inhibitors as antiviral agents?

In a new study, researchers explored sphingosine kinases inhibitors and characterized the role of SKs in Ebola virus (EBOV) entry.

16 Aug 2022

Response to COVID-19 boosters in seronegative multiple sclerosis patients

Researchers report humoral T-cell responses in seronegative MS patients after receiving a third COVID-19 booster vaccine dose.

20 Mar 2022

Induction and stability of vaccine-specific antibodies in multiple sclerosis patients on different disease-modifying therapies

Researchers have investigated the lack of response to treatment in certain multiple sclerosis patients.

9 Feb 2022

An investigation of three SARS-CoV-2 mRNA doses in multiple sclerosis vaccine non-responders

A clinical study by a team of scientists from Norway aimed to assess the immunogenicity and safety of a third dose of COVID-19 mRNA vaccine in MS patients treated with anti-CD20 therapy or fingolimod. A preprint version of the study, which is yet to undergo peer review, is available on the medRxiv* server.

20 Oct 2021

Fighting SARS-CoV-2 with nanomedicine

Published in the Journal of Controlled Release, researchers from the German University in Cairo, and the University of Cologne, looked into nano-reformulation of repurposed antiviral and immune-modulating drugs for inhalation therapy against COVID-19. In addition, they focused on how nanomedicine could address the limitations of current therapeutics, enhancing the efficacy, specificity, and safety of such drugs.

1 Aug 2021

Immunosuppressive therapies may be linked to severe COVID-19 in those with multiple sclerosis

A new study examines the associations between immunosuppressive disease-modifying therapies (DMTs) used in MS with adverse outcomes in an international cohort of patients with MS COVID-19.

15 Feb 2021

Insufficient evidence for cognitive efficacy of drug treatments in multiple sclerosis

Researchers at Kessler Foundation conducted a comprehensive review of pharmacologic agents used in the treatment of multiple sclerosis, seeking evidence for efficacy for the cognitive dysfunction experienced by more than half of affected individuals.

17 Jun 2020

Schizophrenia related to abnormal fatty metabolism in the brain

Researchers discovered a brain deficiency in people with schizophrenia that could lead to development of new drug therapies.

28 Apr 2020

Johns Hopkins researchers identify new way to lower blood pressure in obese patients

There's no question that as body weight increases, so too does blood pressure. Now, in a study of mice, Johns Hopkins researchers have revealed exactly which molecules are likely responsible for the link between obesity and blood pressure.

From Johns Hopkins Medicine 26 Sep 2019

Researchers develop fast diagnostic tool that shows MS patients in relapse

Dr. Horea Rus is an expert in diagnosing and treating patients with multiple sclerosis, and his research laboratory at the University of Maryland is producing new tools for treating the disease that attacks the central nervous system.

8 May 2019

Researchers use structural biology techniques to understand how lipids bind proteins

Normal cells have a complex system of checks and balances that regulate cell division.

30 Apr 2019

Targeting biochemical pathway may lead to new therapies for alleviating symptoms of anxiety disorders

According to some estimates, up to one in three people around the world may experience severe anxiety in their lifetime.

12 Dec 2018

UA pharmacology professors aim to avoid opioid analgesic tolerance

For thousands of Americans, opioids no longer relieve pain -- they cause pain. Known as "opioid tolerance," patients eventually become desensitized to opioids and more sensitive to pain after years of using the pain relievers.

31 Oct 2018

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.

8 Oct 2018

CHMP recommends approval of Gilenya for treatment of multiple sclerosis in children, adolescents

Novartis today announced the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Gilenya (fingolimod) for the treatment of children and adolescents 10 to 17 years of age with relapsing remitting forms of multiple sclerosis.

24 Sep 2018

New combination therapy for cancer cells could soon be a reality

A new cancer therapy using nanoparticles to deliver a combination therapy direct to cancer cells could be on the horizon, thanks to research from the University of East Anglia.

From Precision NanoSystems Inc. 10 Aug 2018